Protein A induces NO production: Involvement of tyrosine kinase, phospholipase C, and protein kinase C

被引:19
作者
Goenka, S
Das, T
Sa, G
Ray, PK
机构
[1] Bose Inst, Immunotechnol Sect, Calcutta 700054, W Bengal, India
[2] Bose Inst, Anim Physiol Sect, Calcutta 700054, W Bengal, India
关键词
D O I
10.1006/bbrc.1998.9324
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein A of S. aureus exhibits a wide array of immunopotentiating activities. Since the role of nitric oxide (NO) in bioregulation has been well envisaged, we studied the effect of Protein A on NO production by immunocytes both in vivo and in vitro. Our data indicate that PA at a comparable dose of LPS (lipopolysaccharide) increases the NO levels in the serum of Swiss albino mice by about 12-fold from its basal level. The peak level is reached at about 12 hours after i.p. inoculation of PA. However, NO concentration returns to the basal value 15 hours posttreatment. Splenic lymphocytes and peritoneal macrophages showed appreciable increase in NO production when cultured with PA in vitro. Interestingly, inhibitors of tyrosine kinase, phospholipase C, and protein kinase C (PKC) inhibited NO production in splenic lymphocytes. Thus, it appears that these enzymes participate in the signaling cascade induced by PA, which culminates in the production of NO downstream of PHC. It is possible that PA-induced NO production may have relevance with the anti-tumor and anti-parasitic properties of PG described earlier, (C) 1998 Academic Press.
引用
收藏
页码:425 / 429
页数:5
相关论文
共 53 条
[1]  
ALBINA JE, 1993, J IMMUNOL, V150, P5080
[2]   APPARENT HYDROXYL RADICAL PRODUCTION BY PEROXYNITRITE - IMPLICATIONS FOR ENDOTHELIAL INJURY FROM NITRIC-OXIDE AND SUPEROXIDE [J].
BECKMAN, JS ;
BECKMAN, TW ;
CHEN, J ;
MARSHALL, PA ;
FREEMAN, BA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (04) :1620-1624
[3]   GAMMA-INTERFERON INDUCED BY S-AUREUS PROTEIN-A AUGMENTS NATURAL KILLING AND ADCC [J].
CATALONA, WJ ;
RATLIFF, TL ;
MCCOOL, RE .
NATURE, 1981, 291 (5810) :77-79
[4]  
CAVAILLON JM, 1997, IMMUNOMODULATION, P111
[5]  
DAS T, 1998, INT C STRESS AD PROP, P8
[6]  
DAS T, 1998, IN PRESS IMMUNOPHARM
[7]  
DERVORT AIV, 1994, J IMMUNOL, V15, P4102
[8]  
DONG ZY, 1993, J IMMUNOL, V151, P2717
[9]  
DRAPIER JC, 1988, J IMMUNOL, V140, P2829
[10]  
FEHSEL K, 1995, J IMMUNOL, V155, P2858